medicationControlledSchedule IV (US)Prescription only (US)FDA-approved (as Belsomra) for the treatment of insomnia characterized by difficulty with sleep onset and/or maintenanceClassified as a Schedule IV controlled substance in the US due to abuse potential
SuvorexantBenefits, Dosage & Interactions
Also known as: Belsomra
Suvorexant, marketed as Belsomra, is a medication primarily used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It belongs to a class of drugs known as dual orexin receptor antagonists (DORAs). It is typically taken in the evening.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~12 h
Typical timing
bedtime
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Suvorexant in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Suvorexant entry is written from. Each number matches an inline marker above.
- [1]Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical TrialsBiological Psychiatry · 2016 · Peer-reviewed · PMID 25526970
- [2]Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysisThe Lancet · 2022 · Peer-reviewed · PMID 35843245
How to track Suvorexant doses
Tracking Suvorexant well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Suvorexant with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is bedtime. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Suvorexant through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 12 h, effects and timing shifts show up over days rather than instantly. Review Suvorexant alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Suvorexant dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Suvorexant?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Suvorexant, marketed as Belsomra, is a medication primarily used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It belongs to a class of drugs known as dual orexin receptor antagonists (DORAs). Unlike some traditional sleep medications that work by enhancing general brain inhibition, suvorexant targets a specific neurochemical system involved in wakefulness. It is available as an oral tablet and is classified as a Schedule IV controlled substance in the United States due to its potential for abuse, though this risk is considered low (FDA label, DrugBank).
The development of suvorexant represents a novel approach to managing insomnia, focusing on suppressing the wake-promoting signals rather than directly sedating the brain. This mechanism is designed to promote sleep more naturally by allowing the body's intrinsic sleep mechanisms to take over. It was approved by the U.S. Food and Drug Administration (FDA) in 2014. Patients considering suvorexant should have a thorough medical evaluation by a licensed clinician to determine its appropriateness for their specific condition.
What does the research say about Suvorexant?
Tap a section to expand.
Suvorexant's primary mechanism of action involves the selective blockade of orexin receptors, specifically both orexin 1 (OX1) and orexin 2 (OX2) receptors. Orexins (also known as hypocretins) are neuropeptides produced by neurons in the lateral hypothalamus that play a crucial role in regulating wakefulness, arousal, and appetite. By binding to and antagonizing these receptors, suvorexant inhibits the binding of wake-promoting orexin neuropeptides. This action suppresses the signaling of the wakefulness system in the brain, thereby promoting the initiation and maintenance of sleep (FDA label, DrugBank).
Unlike benzodiazepines and Z-drugs (which modulate GABAergic neurotransmission), suvorexant does not exert its effects by directly potentiating inhibitory neurotransmission. Instead, it acts upstream by reducing the activity of a key arousal system. The dual antagonism of both OX1 and OX2 receptors is thought to contribute to its efficacy in both sleep onset and sleep maintenance, as both receptor subtypes are implicated in aspects of wakefulness and arousal. The drug reaches peak plasma concentrations approximately 1.5 to 2 hours after oral administration and has an elimination half-life of about 12 hours, which supports its use as a nightly medication for insomnia (FDA label).
Source for this section: Sources for How does Suvorexant work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of suvorexant is its demonstrated efficacy in improving sleep parameters in adults with insomnia. Clinical trials have shown that suvorexant can help patients fall asleep faster and stay asleep longer. Specific benefits observed in studies include:
* **Improved Sleep Onset:** Patients taking suvorexant often report a reduction in subjective sleep latency, meaning they perceive that it takes less time to fall asleep (FDA label, Cochrane review).
* **Enhanced Sleep Maintenance:** The medication has been shown to decrease wakefulness after sleep onset (WASO) and increase total sleep time (TST), indicating better sleep continuity throughout the night (FDA label).
* **Reduced Nighttime Awakenings:** By promoting deeper sleep maintenance, suvorexant can help reduce the frequency and duration of awakenings during the night.
* **Novel Mechanism of Action:** Its distinct mechanism, targeting the orexin system, offers an alternative for patients who may not respond well to or tolerate other classes of hypnotics. This approach avoids some of the challenges associated with GABAergic medications, such as profound sedation or withdrawal effects related to GABA (DrugBank).
* **Potential for Improved Daytime Functioning:** By improving nocturnal sleep, some patients may experience improvements in daytime alertness and overall quality of life, although direct evidence for this is sometimes secondary to sleep improvements (Cochrane review).
It is important to note that the clinical significance of these benefits can vary among individuals, and suvorexant is typically prescribed as part of a comprehensive insomnia management strategy, ideally alongside behavioral therapies such as cognitive behavioral therapy for insomnia (CBT-I) (Mayo Clinic).
Evidence for the efficacy and safety of suvorexant primarily comes from multiple randomized, double-blind, placebo-controlled clinical trials. These studies involved adults with insomnia and assessed various objective and subjective sleep parameters.
* **Sleep Onset and Maintenance:** Trials consistently demonstrated that suvorexant significantly reduced polysomnography-measured sleep latency (time to persistent sleep) and wakefulness after sleep onset (WASO) compared to placebo. It also increased total sleep time (TST). Subjective measures, such as patient-reported sleep latency and TST, also showed significant improvements (FDA label, PubChem).
* **Long-term Efficacy:** Studies extending up to 12 months indicated that improvements in sleep parameters were generally maintained with continued use, without significant evidence of tolerance development (FDA label).
* **Comparison with Other Hypnotics:** While direct head-to-head comparisons are limited, suvorexant's efficacy has been shown to be comparable to some other hypnotics in certain sleep parameters, though its distinct mechanism offers a different therapeutic profile (Examine.com).
* **Safety Profile:** The overall safety profile of suvorexant has been established through these trials, identifying common side effects and rare but serious adverse events. Long-term studies contributed to understanding its safety over an extended period (FDA label).
Results from meta-analyses and systematic reviews, such as those conducted by Cochrane, generally support suvorexant's efficacy in improving sleep parameters in patients with insomnia. However, these reviews also often highlight the need for careful patient selection and monitoring due to the potential for adverse effects and the characteristics of the target population for insomnia treatments (Cochrane Library).
Like all medications, suvorexant can cause side effects, though not everyone experiences them. The most commonly reported side effects in clinical trials include:
* Drowsiness or somnolence (feeling sleepy during the day)
* Headache
* Dizziness
* Abnormal dreams or nightmares
* Dry mouth
* Upper respiratory tract infections
* Diarrhea
* Fatigue
Less common but more serious side effects may include:
* **Next-day impairment:** Even with a full night's sleep, suvorexant can cause next-day drowsiness and impaired driving ability or other psychomotor skills. This risk is higher with higher doses and if taken without sufficient time for elimination (e.g., less than 7 hours of sleep anticipated).
* **Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms:** These are conditions where individuals may experience temporary inability to move during sleep onset or offset, vivid perceptions despite being awake, or sudden muscle weakness with emotional triggers. These symptoms are related to the orexin system and have been reported, particularly at higher doses.
* **Worsening depression or suicidal ideation:** Suvorexant should be used with caution in patients with depression, as it may exacerbate symptoms, including suicidal thoughts and behaviors.
* **Complex sleep behaviors:** Rare but serious behaviors such as sleep-driving, sleep-eating, making phone calls, or engaging in other activities while not fully awake, and having no memory of them, can occur. These behaviors can be dangerous.
* **Anxiety, agitation, or aggression:** Paradoxical reactions such as these have been reported.
* **Dependence and withdrawal:** While the risk of physical dependence and withdrawal symptoms is considered lower than with benzodiazepines, suvorexant is a controlled substance, and abrupt discontinuation can lead to temporary worsening of insomnia or other rebound effects.
Patients should report any side effects to their clinician. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several warnings and precautions should be considered before and during suvorexant treatment:
* **Next-Day Impairment:** Suvorexant can cause residual effects such as drowsiness, impaired attention, concentration, and motor coordination the morning after use. Patients should be cautioned about engaging in activities requiring complete mental alertness, such as driving or operating machinery, until they are certain the medication has no such effects on them. The risk is higher with higher doses and if less than 7 hours of sleep are obtained (FDA label).
* **CNS Depressant Effects:** Suvorexant has central nervous system (CNS) depressant effects. Concomitant use with other CNS depressants, including alcohol, opioids, and other sedatives, can increase these effects and lead to additive impairment (FDA label).
* **Worsening of Depression/Suicidal Ideation:** Like other hypnotics, suvorexant should be administered with caution in patients exhibiting symptoms of depression. Worsening of depression and suicidal thinking and behavior have been reported (FDA label).
* **Complex Sleep Behaviors:** Cases of complex sleep behaviors, including sleep-driving, engaging in activities while not fully awake (e.g., preparing and eating food, making phone calls), and having no memory of the event, have been reported. These behaviors can result in serious injuries, including death. Immediate discontinuation should be considered if such behaviors occur (FDA label).
* **Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations:** These experiences have been reported, particularly at higher doses. Patients who experience these phenomena should be evaluated by a clinician (FDA label).
* **Cataplexy-like Symptoms:** Mild cataplexy-like symptoms have been observed in clinical trials, especially at doses higher than recommended. Patients with narcolepsy should not use suvorexant (FDA label).
* **Respiratory Depression:** While not a primary effect, caution is advised in patients with compromised respiratory function, such as those with sleep apnea or chronic obstructive pulmonary disease (COPD), though studies have not shown significant respiratory depression at recommended doses (FDA label).
* **Abuse Potential:** Suvorexant is a Schedule IV controlled substance, indicating a potential for abuse, though the risk is considered low. Patients should be assessed for a history of drug abuse before initiating treatment (FDA label).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Suvorexant is contraindicated in specific situations due to the risk of serious adverse effects. Absolute contraindications include:
* **Narcolepsy:** Due to its mechanism of action, which involves the orexin system, suvorexant is absolutely contraindicated in patients with narcolepsy. Orexin signaling is disrupted in narcolepsy, and administering an orexin receptor antagonist could worsen the symptoms of narcolepsy, particularly cataplexy (FDA label).
* **Hypersensitivity:** Known hypersensitivity to suvorexant or any of its excipients is a contraindication. Allergic reactions, including angioedema and anaphylaxis, have been reported (FDA label).
* **Severe Hepatic Impairment:** Suvorexant is extensively metabolized by the liver, primarily via cytochrome P450 3A (CYP3A). In patients with severe hepatic impairment, the clearance of suvorexant is significantly reduced, leading to increased plasma concentrations and a higher risk of adverse effects. Therefore, suvorexant is not recommended for use in this population (FDA label).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given its metabolic pathway and central nervous system (CNS) depressant effects, suvorexant has several important drug interactions and should not be mixed with certain substances unless specifically advised and monitored by a clinician:
* **Strong CYP3A Inhibitors:** Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, telithromycin) is contraindicated. These drugs significantly increase suvorexant exposure, leading to prolonged and increased CNS depressant effects and a higher risk of adverse reactions (FDA label).
* **Moderate CYP3A Inhibitors:** The dose of suvorexant should be reduced when co-administered with moderate CYP3A inhibitors (e.g., diltiazem, verapamil, fluconazole, grapefruit juice) due to increased suvorexant concentrations. Consultation with a clinician is essential (FDA label).
* **Other CNS Depressants:** Co-administration with alcohol, opioids, benzodiazepines, tricyclic antidepressants, anxiolytics, sedatives, antihistamines, and other CNS depressants can lead to additive CNS depressant effects, including increased sedation, dizziness, impaired psychomotor performance, and respiratory depression. This combination should be avoided or used with extreme caution and close monitoring (FDA label, DrugBank).
* **CYP3A Inducers:** Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin) can significantly decrease suvorexant exposure, potentially reducing its efficacy. Co-administration should generally be avoided or managed with careful clinical judgment (FDA label).
Always inform your clinician about all medications, supplements, and herbal products you are currently using to avoid potentially harmful interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Suvorexant should be taken orally, typically once per night, within 30 minutes before going to bed. It is important to take it only when you can dedicate a full night's sleep of at least 7 hours. Taking it when less than 7 hours of sleep is possible can increase the risk of next-day impairment, including drowsiness and impaired driving ability (FDA label).
The medication can be taken with or without food. However, taking suvorexant with or immediately after a heavy meal may delay its absorption and consequently delay its effects, potentially affecting sleep onset (FDA label). For optimal effect, some find it best to take it on an empty stomach or at least a couple of hours after their last meal. Consistent timing each night is generally recommended to help establish a regular sleep-wake cycle.
Source for this section: Sources for When should you take Suvorexant?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Suvorexant?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Melatonin | Note | Compound pairConfidence: theoretical | Additive sedation possible.Source pending | Start at low melatonin dose (0.3–1 mg) when combined with prescription sedatives. |
Frequently asked questions about Suvorexant
Suvorexant is a Schedule IV controlled substance, indicating it has a lower potential for abuse compared to Schedule III substances but still carries some risk. While the risk of physical dependence and withdrawal symptoms is considered lower than with benzodiazepines, abrupt discontinuation after prolonged use can lead to temporary worsening of insomnia or other rebound effects. Discuss any concerns about dependence with your clinician.
Suvorexant typically starts to work within 30 minutes to an hour after taking it. However, the exact onset of action can vary depending on individual metabolism, whether it's taken with food (a heavy meal can delay absorption), and other factors. It's crucial to take it only when you have at least 7 hours available for sleep.
No, it is strongly advised to avoid alcohol consumption while taking suvorexant. Both alcohol and suvorexant are central nervous system (CNS) depressants. Combining them can lead to additive CNS depressant effects, resulting in increased sedation, dizziness, impaired coordination, and potentially dangerous respiratory depression. This combination can severely impair your ability to drive or perform other tasks requiring alertness.
Clinical trials have evaluated the safety and efficacy of suvorexant for up to 12 months, with results suggesting that improvements in sleep parameters are generally maintained without significant evidence of tolerance development. However, the long-term use of any sleep medication should be periodically re-evaluated by a licensed clinician to ensure it remains the most appropriate treatment and that potential risks do not outweigh the benefits. Your clinician will determine if long-term use is suitable for your specific condition.
If you experience unusual sensations such as temporary inability to move while falling asleep or waking up (sleep paralysis), or vivid perceptions of sounds, images, or feelings that aren't real (hypnagogic/hypnopompic hallucinations), you should contact your clinician immediately. While these can be related to the orexin system and have been reported with suvorexant, they warrant medical evaluation as they can be distressing or indicate other underlying issues. Your clinician may adjust your dosage or consider alternative treatments.
Suvorexant is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Suvorexant is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 12 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Suvorexant with no sign-up.
Suvorexant is typically taken in the evening. The reported plasma half-life is about 12 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a medication like Suvorexant with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Suvorexant: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 12 hours, once-daily dosing is the usual pattern for Suvorexant. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 12 hours, a single missed dose of Suvorexant usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Suvorexant the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Suvorexant?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis(opens PubMed in a new tab)Transl Psychiatry · 2025 · PMID 40555730 · https://pubmed.ncbi.nlm.nih.gov/40555730/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 24965990(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/24965990
Verify at
Publisher search links for Suvorexant. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Suvorexant?
Plain-text summary, safe to quote verbatim:
Suvorexant, marketed as Belsomra, is a medication primarily used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It belongs to a class of drugs known as dual orexin receptor antagonists (DORAs). It is typically taken in the evening.
Source: DoseRoutine — https://doseroutine.com/library/suvorexant
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Suvorexant — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/suvorexant
What compounds are similar to Suvorexant?
Others in the medication category or studied for the same goals.